# US 2020/0239858 A1 · Recombinant vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0239858 A1
- Document ID: US20200239858A1
- Status: Published application
- Kind: A1
- Application number: 16/560,525
- Filed: 2019-09-04
- Published: 2020-07-30
- Earliest claimed: 2008-09-26
- Assignees: Tocagen Inc.
- Applicants: Tocagen Inc.
- Inventors: Harry E. Gruber; Douglas J. Jolly; Omar D. Perez; Christopher R. Logg
- Web page: https://patentgrep.com/patent/US20200239858A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 38/2292: {Thymosin; Related peptides}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/86: Viral vectors
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2760/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

## Claims

### Claim at position 1

1-60. (canceled)

### Claim 61

A recombinant replication competent gammaretrovirus comprising:
a gammaretroviral GAG protein;
a gammaretroviral POL protein;
a gammaretroviral envelope;
a gammaretroviral RNA polynucleotide comprising 3′ untranslated region (U3) and repeat region (R) sequences from murine leukemia virus (MLV), Moloney murine leukemia virus (MoMLV), Feline leukemia virus (FeLV), Baboon endogenous retrovirus (BEV), porcine endogenous virus (PERV), the cat derived retrovirus RD114, squirrel monkey retrovirus, Xenotropic murine leukemia virus-related virus(XMRV), avian reticuloendotheliosis virus(REV), or Gibbon ape leukemia virus (GALV) at the 3′ end of the gammaretroviral polynucleotide sequence, an R and 5′ untranslated region (U5) sequence from MLV, MoMLV, FeLV, BEV, PERV, RD114, squirrel monkey retrovirus, XMRV, REV or GALV at the 5′ end of the gammaretroviral polynucleotide, a gag nucleic acid domain, a pol nucleic acid domain and an env nucleic acid domain from MLV, MoMLV, FeLV, BEV, PERV, RD114, squirrel monkey retrovirus, XMRV, REV or GALV located between the U5 and U3 regions;
a cassette comprising an internal ribosome entry site (IRES) upstream and operably linked to a heterologous polynucleotide followed by pol-III promoter linked to an inhibitory polynucleotide, wherein the cassette is positioned 5′ to the U3 region and 3′ to the env nucleic acid domain; and
cis-acting sequences necessary for reverse transcription, packaging and integration in a target cell.

### Claim 62 (depends on 61)

The retrovirus according to claim 61, wherein the heterologous nucleic acid encodes a polypeptide that converts a nontoxic prodrug in to a toxic drug.

### Claim 63 (depends on 61)

The retrovirus of claim 61, wherein the retroviral envelope is an amphotropic MLV envelope.

### Claim 64 (depends on 62)

The retrovirus according to claim 62, wherein the polypeptide that converts a nontoxic prodrug in to a toxic drug is thymidine kinase, purine nucleoside phosphorylase (PNP), or cytosine deaminase

### Claim 65 (depends on 61)

The retrovirus according to claim 61, wherein the heterologous nucleic acid sequence encodes a binding domain, an antibody, or antibody fragment.

### Claim 66 (depends on 61)

The retrovirus of claim 61, wherein the retrovirus infects cancer cells of a cancer.

### Claim 67 (depends on 66)

The retrovirus of claim 66, wherein the cancer is selected from the group consisting of lung cancer, colon-rectum cancer, breast cancer, prostate cancer, urinary tract cancer, uterine cancer, brain cancer, head and neck cancer, pancreatic cancer, melanoma, stomach cancer and ovarian cancer.

### Claim 68 (depends on 61)

The retrovirus of claim 61, wherein the pol III promoter is an H1 or U6 promoter.

### Claim 69 (depends on 61)

The retrovirus according to claim 61, wherein the inhibitory polynucleotide comprises an miRNA, RNAi or siRNA sequence.

### Claim 70 (depends on 61)

A method of treating a cell proliferative disorder comprising administering the recombinant replication competent gammaretrovirus of claim 61 to a subject having a cell proliferative disorder under conditions such that the retrovirus infects cells with the disorder and contacting the subject with an anti-cancer agent or chemotherapeutic agent, wherein the retrovirus is administered from about 103 to 1011 TU/g brain weight.

### Claim 71 (depends on 70)

The method of claim 70, wherein the anti-cancer agent is selected from the group consisting of bevacizumab, pegaptanib, ranibizumab, sorafenib, sunitinib, AE-941, VEGF Trap, pazopanib, vandetanib, vatalanib, cediranib, fenretinide, squalamine, INGN-241, oral tetrathiomolybdate, tetrathiomolybdate, Panzem NCD, 2-methoxyestradiol, AEE-788, AG-013958, bevasiranib sodium, AMG-706, axitinib, BIBF-1120, CDP-791, CP-547632, PI-88, SU-14813, SU-6668, XL-647, XL-999, IMC-1121 B, ABT-869, BAY-57-9352, BAY-73-4506, BMS-582664, CEP-7055, CHIR-265, CT-322, CX-3542, E-7080, ENMD-1198, OSI-930, PTC-299, Sirna-027, TKI-258, Veglin, XL-184, or ZK-304709.
